株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

シェーグレン症候群(SS)- 市場洞察、疫学、市場予測 2028年

Sjogren's Syndrome (SS) - Market Insights, Epidemiology and Market Forecast-2028

発行 DelveInsight Business Research LLP 商品コード 602095
出版日 ページ情報 英文 192 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=107.66円で換算しております。
Back to Top
シェーグレン症候群(SS)- 市場洞察、疫学、市場予測 2028年 Sjogren's Syndrome (SS) - Market Insights, Epidemiology and Market Forecast-2028
出版日: 2019年08月01日 ページ情報: 英文 192 Pages
概要

主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)におけるシェーグレン症候群(SS)の有病数は、2017年に327万396人と推計されています。

主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)のシェーグレン症候群(SS)市場を調査し、市場の概要、疾病概要、性別・タイプ別・重症度別の症例数、上市済み治療薬および新薬の概要、治療薬別の市場規模、市場の成長要因および障壁などについてまとめています。

目次

第1章 重要洞察

第2章 シェーグレン症候群(SS)の市場概要

  • 市場シェア(実数値)
  • 市場シェア(予測値)

第3章 疾病概要:シェーグレン症候群

  • イントロダクション
  • シェーグレン症候群(SS)の分類
  • 兆候と症状
  • 病因
  • シェーグレン症候群(SS)のバイオマーカー
  • シェーグレン症候群(SS)の診断
    • 鑑別診断

第4章 疫学と患者人口

  • 主な調査結果
  • 主要7カ国のシェーグレン症候群(SS)の有病数
  • 国別の疫学
  • 米国
    • 仮定と根拠
    • 診断有病数
    • 症例数:性別
    • 症例数:タイプ別
    • 症例数:重症度別
  • ドイツ
    • 診断有病数
    • 症例数:性別
    • 症例数:タイプ別
    • 症例数:重症度別
  • フランス
    • 診断有病数
    • 症例数:性別
    • 症例数:タイプ別
    • 症例数:重症度別
  • イタリア
    • 診断有病数
    • 症例数:性別
    • 症例数:タイプ別
    • 症例数:重症度別
  • スペイン
    • 診断有病数
    • 症例数:性別
    • 症例数:タイプ別
    • 症例数:重症度別
  • 英国
    • 診断有病数
    • 症例数:性別
    • 症例数:タイプ別
    • 症例数:重症度別
  • 日本
    • 診断有病数
    • 症例数:性別
    • 症例数:タイプ別
    • 症例数:重症度別

第5章 現行の治療法

  • シェーグレン症候群(SS)の米国治療ガイドライン
  • エビデンスに基づいた医療の診療ガイドライン(米国、欧州、日本)

第6章 アンメットニーズ

第7章 上市済み治療薬

  • Salagen:ADVANZ Pharma
    • 医薬品概要
    • 規制のマイルストーン
    • 安全性と有効性
    • 製品プロファイル
  • Evoxac:第一三共
    • 臨床開発

第8章 新薬

  • 主要なクロスコンペティション
  • RSLV-132:Resolve Therapeutics
    • 医薬品概要
    • その他の開発動向
    • 臨床開発
    • 安全性と有効性
    • 製品プロファイル
  • VAY736:Novartis/MorphoSys
  • CFZ533:Novartis
  • Belimumab:GlaxoSmithKline
  • RO5459072:Roche
  • LOU-064:Novartis
  • Abatacept:Bristol Myers Squibb
  • Lacripep:TearSolutions
  • Parsaclisib:Incyte Corporation
  • Filgotinib:Galapagos NV/Gilead Sciences
  • GS-9876:Gilead Sciences
  • VIB7734:VIELABIO

第9章 主要7カ国のシェーグレン症候群(SS)市場

  • 主な調査結果
  • 主要7カ国のシェーグレン症候群(SS)の市場規模

第10章 市場見通し:国別

第11章 米国:市場の見通し

  • 米国の市場規模
    • シェーグレン症候群(SS)の総市場規模
    • 原発性シェーグレン症候群の市場規模:治療薬別
    • 続発性シェーグレン症候群の市場規模:治療薬別

第12章 欧州5カ国市場の見通し

  • ドイツ
    • シェーグレン症候群(SS)の総市場規模
    • 原発性シェーグレン症候群の市場規模:治療薬別
    • 続発性シェーグレン症候群の市場規模:治療薬別
  • フランス
  • イタリア
  • スペイン
  • 英国
  • 日本

第13章 市場の成長要因

第14章 市場の障壁

章15:付録

第16章 調査方法

第17章 DelveInsightのサービス内容

第18章 免責事項

第19章 DelveInsightについて

第20章 免責事項

図表

List of Tables

  • Table 1: American-European Consensus Group Criteria- Revised international classification criteria for Sjogren's syndrome
  • Table 2: Revised rules for classification - American-European Consensus Group Criteria
  • Table 3: ACR/EULAR criteria
  • Table 4: Selected Non-HLA genes implicated in SS
  • Table 5: Biomarkers in Primary Sjogren's syndrome
  • Table 6: Diagnostic tests to evaluate sicca symptoms in patients with Sjogren's Syndrome
  • Table 7: Evaluation of Dry Eye
  • Table 8: Comparison of the Revised AECG Classification criteria and the ACR Classification criteria for Sjogren's syndrome
  • Table 9: Diagnosed Prevalent Patient Population of Sjogren's syndrome in 7MM (2017-2028)
  • Table 10: Diagnosed Prevalent Cases of Sjogren's syndrome in the United States (2017-2028)
  • Table 11: Gender-specific cases of Sjogren's syndrome in the United States (2017-2028)
  • Table 12: Type-specific Cases of Sjogren's syndrome in the United States (2017-2028)
  • Table 13: Severity-specific Cases of Sjogren's syndrome in the United States (2017-2028)
  • Table 14: Diagnosed Prevalent Cases of Sjogren's syndrome in Germany (2017-2028)
  • Table 15: Gender-specific cases of Sjogren's syndrome in Germany (2017-2028)
  • Table 16: Type-specific Cases of Sjogren's syndrome in Germany (2017-2028)
  • Table 17: Severity-specific Cases of Sjogren's syndrome in Germany (2017-2028)
  • Table 18: Diagnosed Prevalent Cases of Sjogren's syndrome in France (2017-2028)
  • Table 19: Gender-specific cases of Sjogren's syndrome in France (2017-2028)
  • Table 20: Type-specific Cases of Sjogren's syndrome in France (2017-2028)
  • Table 21: Severity-specific Cases of Sjogren's syndrome in France (2017-2028)
  • Table 22: Diagnosed Prevalent Cases of Sjogren's syndrome in Italy (2017-2028)
  • Table 23: Gender-specific cases of Sjogren's syndrome in Italy (2017-2028)
  • Table 24: Type-specific Cases of Sjogren's syndrome in Italy (2017-2028)
  • Table 25: Severity-specific Cases of Sjogren's syndrome in Italy (2017-2028)
  • Table 26: Diagnosed Prevalent Cases of Sjogren's syndrome in Spain (2017-2028)
  • Table 27: Gender-specific cases of Sjogren's syndrome in Spain (2017-2028)
  • Table 28: Type-specific Cases of Sjogren's syndrome in Spain (2017-2028)
  • Table 29: Severity-specific Cases of Sjogren's syndrome in Spain (2017-2028)
  • Table 30: Diagnosed Prevalent Cases of Sjogren's syndrome in the United Kingdom (2017-2028)
  • Table 31: Gender-specific cases of Sjogren's syndrome in the United Kingdom (2017-2028)
  • Table 32: Type-specific Cases of Sjogren's syndrome in the UK (2017-2028)
  • Table 33: Severity-specific Cases of Sjogren's syndrome in the United Kingdom (2017-2028)
  • Table 34: Diagnosed Prevalent Cases of Sjogren's syndrome in Japan (2017-2028)
  • Table 35: Gender-specific cases of Sjogren's syndrome in Japan (2017-2028)
  • Table 36: Type-specific Cases of Sjogren's syndrome in Japan (2017-2028)
  • Table 37: Severity-specific Cases of Sjogren's syndrome in Japan (2017-2028)
  • Table 38: Oral management guidelines for caries prophylaxis
  • Table 39: Guidelines for DMARDS use for musculoskeletal pain in SS
  • Table 40: Guidelines for the treatment of fatigue in Sjogren's disease
  • Table 41: Guidelines for the use of biological medications in Sjogren's disease
  • Table 42: Currently available evidence-based medicine clinical practice guidelines on diagnosis and management of SS
  • Table 43: Evoxac, Clinical Trial Description, 2018
  • Table 44: Emerging Drugs Analysis
  • Table 45: Emerging Drugs Analysis
  • Table 46: RSLV-132, Clinical Trial Description, 2019
  • Table 47: VAY736, Clinical Trial Description, 2019
  • Table 48: CFZ533, Clinical Trial Description, 2018
  • Table 49: Belimumab, Clinical Trial Description, 2019
  • Table 50: RO5459072, Clinical Trial Description, 2019
  • Table 51: LOU-064, Clinical Trial Description, 2019
  • Table 52: Abatacept, Clinical Trial Description, 2019
  • Table 53: Lacripep, Clinical Trial Description, 2019
  • Table 54: Parsaclisib, Clinical Trial Description, 2019
  • Table 55: Filgotinib, Clinical Trial Description, 2019
  • Table 56: GS-9876, Clinical Trial Description, 2019
  • Table 57: VIB7734, Clinical Trial Description, 2019
  • Table 58: 7 Major Market Size of Sjogren's syndrome in USD Million (2017-2028)
  • Table 59: United States Market Size of Sjogren's syndrome in USD Million (2017-2028)
  • Table 60: Market Size of Primary Sjogren's syndrome by Therapies in USD Million (2017-2028)
  • Table 61: Market Size of Secondary Sjogren's syndrome by Therapies in USD Million (2017-2028)
  • Table 62: Germany Market Size of Sjogren's syndrome in USD Million (2017-2028)
  • Table 63: Market Size of Primary Sjogren's syndrome by Therapies in USD Million (2017-2028)
  • Table 64: Market Size of Secondary Sjogren's syndrome by Therapies in USD Million (2017-2028)
  • Table 65: France Market Size of Sjogren's syndrome in USD Million (2017-2028)
  • Table 66: Market Size of Primary Sjogren's syndrome by Therapies in USD Million (2017-2028)
  • Table 67: Market Size of Secondary Sjogren's syndrome by Therapies in USD Million (2017-2028)
  • Table 68: Italy, Market Size of Sjogren's syndrome in USD Million (2017-2028)
  • Table 69: Market Size of Primary Sjogren's syndrome by Therapies in USD Million (2017-2028)
  • Table 70: Market Size of Secondary Sjogren's syndrome by Therapies in USD Million (2017-2028)
  • Table 71: Spain, Market Size of Sjogren's syndrome in USD Million (2017-2028)
  • Table 72: Market Size of Primary Sjogren's syndrome by Therapies in USD Million (2017-2028)
  • Table 73: Market Size of Secondary Sjogren's syndrome by Therapies in USD Million (2017-2028)
  • Table 74: UK Market Size of Sjogren's syndrome in USD Million (2017-2028)
  • Table 75: Market Size of Primary Sjogren's syndrome by Therapies in USD Million (2017-2028)
  • Table 76: Market Size of Secondary Sjogren's syndrome by Therapies in USD Million (2017-2028)
  • Table 77: Japan, Market Size of Sjogren's syndrome in USD Million (2017-2028)
  • Table 78: Market Size of Primary Sjogren's syndrome by Therapies in USD Million (2017-2028)
  • Table 79:Market Size of Secondary Sjogren's syndrome by Therapies in USD Million (2017-2028)

List of Figures

  • Figure 1: Clinical spectrum Sjogren's syndrome
  • Figure 2: The Pathogenesis of autoimmune epitelitis as a potential explanation for Sjogren's Syndrome
  • Figure 3: Interplay of immune and non-immune factors in the pathophysiology of Sjogren's Syndrome
  • Figure 4: Diagnosed Prevalent Patient Population of Sjogren's syndrome in 7MM (2017-2028)
  • Figure 5: Diagnosed Prevalent Cases of Sjogren's syndrome in the United States (2017-2028)
  • Figure 6: Gender-specific Diagnosed Prevalent Cases of Sjogren's syndrome in the US (2017-2028)
  • Figure 7: Type-specific Diagnosed Prevalent Cases of Sjogren's syndrome in the US (2017-2028)
  • Figure 8: Severity-specific Cases of Sjogren's syndrome in the US (2017-2028)
  • Figure 9: Diagnosed Prevalent Cases of Sjogren's syndrome in Germany (2017-2028)
  • Figure 10: Gender-specific of Sjogren's syndrome in Germany (2017-2028)
  • Figure 11: Type-specific Diagnosed Prevalent Cases of Sjogren's syndrome in Germany (2017-2028)
  • Figure 12: Severity-specific Cases of Sjogren's syndrome in Germany (2017-2028)
  • Figure 13: Diagnosed Prevalent Cases of Sjogren's syndrome in France (2017-2028)
  • Figure 14: Gender-specific Cases of Sjogren's syndrome in France (2017-2028)
  • Figure 15: Type-specific Diagnosed Prevalent Cases of Sjogren's syndrome in France (2017-2028)
  • Figure 16: Severity-specific Cases of Sjogren's syndrome in France (2017-2028)
  • Figure 17: Diagnosed Prevalent Cases of Sjogren's syndrome in Italy (2017-2028)
  • Figure 18: Gender-specific Cases of Sjogren's syndrome in Italy (2017-2028)
  • Figure 19: Type-specific Diagnosed Prevalent Cases of Sjogren's syndrome in Italy (2017-2028)
  • Figure 20: Severity-specific Cases of Sjogren's syndrome in Italy (2017-2028)
  • Figure 21: Diagnosed Prevalent Cases of Sjogren's syndrome in Spain (2017-2028)
  • Figure 22: Gender-specific Cases of Sjogren's syndrome in Spain (2017-2028)
  • Figure 23: Type-specific Diagnosed Prevalent Cases of Sjogren's syndrome in Spain (2017-2028)
  • Figure 24: Severity-specific Cases of Sjogren's syndrome in Spain (2017-2028)
  • Figure 25: Diagnosed Prevalent Cases of Sjogren's syndrome in the United Kingdom (2017-2028)
  • Figure 26: Gender-specific Cases of Sjogren's syndrome in the United Kingdom (2017-2028)
  • Figure 27: Type-specific Diagnosed Prevalent Cases of Sjogren's syndrome in the UK (2017-2028)
  • Figure 28: Severity-specific Cases of Sjogren's syndrome in the UK (2017-2028)
  • Figure 29: Diagnosed Prevalent Cases of Sjogren's syndrome in Japan (2017-2028)
  • Figure 30: Gender-specific Cases of Sjogren's syndrome in Japan (2017-2028)
  • Figure 31: Type-specific Diagnosed Prevalent Cases of Sjogren's syndrome in Japan (2017-2028)
  • Figure 32: Severity -specific Cases of Sjogren's syndrome in Japan (2017-2028)
  • Figure 33: Unmet Needs of Sjogren's syndrome
  • Figure 34: 7 Major Market Size of Sjogren's syndrome in USD Million (2017-2028)
  • Figure 35: Market Size of Sjogren's syndrome in the United States, USD Millions (2017-2028)
  • Figure 36: Market Size of Primary Sjogren's syndrome by Therapies in USD Million (2017-2028)
  • Figure 37: Market Size of Secondary Sjogren's syndrome by Therapies in USD Million (2017-2028)
  • Figure 38: Market Size of Sjogren's syndrome in Germany, USD Millions (2017-2028)
  • Figure 39: Market Size of Primary Sjogren's syndrome by Therapies in USD Million (2017-2028)
  • Figure 40: Market Size of Secondary Sjogren's syndrome by Therapies in USD Million (2017-2028)
  • Figure 41: Market Size of Sjogren's syndrome in France, USD Millions (2017-2028)
  • Figure 42: Market Size of Primary Sjogren's syndrome by Therapies in USD Million (2017-2028)
  • Figure 43: Market Size of Secondary Sjogren's syndrome by Therapies in USD Million (2017-2028)
  • Figure 44: Market Size of Sjogren's syndrome in Italy, USD Millions (2017-2028)
  • Figure 45: Market Size of Primary Sjogren's syndrome by Therapies in USD Million (2017-2028)
  • Figure 46: Market Size of Secondary Sjogren's syndrome by Therapies in USD Million (2017-2028)
  • Figure 47: Market Size of Sjogren's syndrome in Spain, USD Millions (2017-2028)
  • Figure 48: Market Size of Primary Sjogren's syndrome by Therapies in USD Million (2017-2028)
  • Figure 49: Market Size of Secondary Sjogren's syndrome by Therapies in USD Million (2017-2028)
  • Figure 50: Market Size of Sjogren's syndrome in the UK, USD Millions (2017-2028)
  • Figure 51: Market Size of Primary Sjogren's syndrome by Therapies in USD Million (2017-2028)
  • Figure 52: Market Size of Secondary Sjogren's syndrome by Therapies in USD Million (2017-2028)
  • Figure 53: Market Size of Sjogren's syndrome in Japan, USD Millions (2017-2028)
  • Figure 54: Market Size of Primary Sjogren's syndrome by Therapies in USD Million (2017-2028)
  • Figure 55: Market Size of Secondary Sjogren's syndrome by Therapies in USD Million (2017-2028)
  • Figure 56: Market Drivers
  • Figure 57: Market Barriers
目次
Product Code: DIMI0339

DelveInsight's 'Sjogren's Syndrome (SS)-Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of Sjogren's Syndrome in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Sjogren's Syndrome from 2017 to 2028 segmented by seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2028

Sjogren's Syndrome - Disease Understanding and Treatment Algorithm

The DelveInsight Sjogren's Syndrome market report gives a thorough understanding of SS by including details, such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Sjogren's Syndrome in the US, Europe, and Japan.

Sjogren's Syndrome Epidemiology

The Sjogren's Syndrome epidemiology division provide insights about historical and current patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report is segmented by Diagnosed Prevalent cases, Gender-specific cases, Type-specific cases [Primary Sjogren's Syndrome (pSS), Secondary Sjogren's Syndrome (sSS)] and Severity-specific cases [Mild and Moderate to Severe] in the 7MM.

According to DelveInsight, the total diagnosed prevalent cases of Sjogren's Syndrome were 3,270,396 in 2017 in 7MM.

Sjogren's Syndrome Drug Chapters

This segment of the Sjogren's Syndrome report encloses the detailed analysis of marketed drugs and late stage (Phase-II and III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Sjogren's Syndrome Market Outlook

The Sjogren's Syndrome market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.

This segment gives a thorough detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

The current market of SS is majorly driven by the growing prevalence and awareness, development of better classification criteria, increased research and development and identification of potential biomarkers. Sjogren's syndrome is a multisystem disorder that is heterogeneous in its presentation, course, and outcome. There is still no single clinical, laboratory, pathological, or radiological feature that could serve as a 'gold standard' for the diagnosis and/or classification of this syndrome. Labial salivary gland biopsy with a subsequent histopathological evaluation is currently in use. Consequently, the development of criteria for use in both clinical care, as well as research studies, has been an important challenge in Sjogren's syndrome. Hitherto, the therapeutic market size of Sjogren's syndrome is mainly accounted by symptomatic treatment including local therapies (pilocarpine, cevimeline, topical fluoride, topical cyclosporine, autologous serum eye drops, and others), systemic therapies (corticosteroids, hydroxychloroquine) and immunosuppressants (Methotrexate (MTX), Cyclosporine A, Azathioprine, Leflunomide, and Mycophenolic acid) which are commonly used interventions. Moreover, biological therapy with Rituximab is in extensive use for the US market.

As per DelveInsight estimates, the market size of SS was found to be USD 2,427.47 million in 2017. This market is further expected to grow during the forecasted period of 2019-2028 owing to the launch of upcoming therapies. Detailed chapters of the promising upcoming therapies, including RSLV-132(Resolve Therapeutics), VAY 736 (Novartis), CFZ533 (Novartis), Belimumab (GlaxoSmithKline), R05459072 (Roche), LOU-064 (Novartis), Abatacept (Bristol Myers Squibb), Lacricep (Tearsolutions), Parsaclisib (Incyte Corporation), Filgotinib (Gilead Sciences), GS-9876 (Gilead Sciences), and VIB7734 (VIELABIO), etc. are also provided in the report.

Sjogren's Syndrome Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017 to 2028. The analysis covers market uptake by drugs; patient uptake by therapies, and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Sjogren's Syndrome Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Sjogren's Syndrome Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Sjogren's Syndrome Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Sjogren's Syndrome market.
  • Organize sales and marketing efforts by identifying the best opportunities for Sjogren's Syndrome market.
  • To understand the future market competition in the Sjogren's Syndrome market.

Table of Contents

1. Key Insights

2. Sjogren's Syndrome (SS): Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of SS in 2017
  • 2.2. Market Share (%) Distribution of SS in 2028

3. Disease Overview: Sjogren's syndrome

  • 3.1. Introduction
  • 3.2. Classification of Sjogren's Syndrome
  • 3.3. Signs and Symptoms
  • 3.4. Etiology
  • 3.5. Pathogenesis
  • 3.6. Biomarkers in Sjogren's Syndrome
  • 3.7. Diagnosis of Sjogren's Syndrome
    • 3.7.1. Differential Diagnosis

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. 7MM Total Diagnosed Prevalent Patient Population of Sjogren's Syndrome
  • 4.3. Country Wise-Epidemiology of Sjogren's syndrome
  • 4.4. United States
    • 4.4.1. Assumptions and Rationale
    • 4.4.2. Diagnosed Prevalent Cases of Sjogren's syndrome in the United States
    • 4.4.3. Gender-Specific Cases of Sjogren's syndrome in the US
    • 4.4.4. Type-Specific Cases of Sjogren's syndrome in the US
    • 4.4.5. Severity-Specific Cases of Sjogren's syndrome in the US
  • 4.5. Germany
    • 4.5.1. Assumptions and Rationale
    • 4.5.2. Diagnosed Prevalent Cases of Sjogren's syndrome in Germany
    • 4.5.3. Gender-Specific Cases of Sjogren's syndrome in Germany
    • 4.5.4. Type-Specific Cases of Sjogren's syndrome in Germany
    • 4.5.5. Severity-Specific Cases of Sjogren's syndrome in Germany
  • 4.6. France
    • 4.6.1. Assumptions and Rationale
    • 4.6.2. Diagnosed Prevalent Cases of Sjogren's syndrome in France
    • 4.6.3. Gender-Specific Cases of Sjogren's syndrome in France
    • 4.6.4. Type-Specific Cases of Sjogren's syndrome in France
    • 4.6.5. Severity-Specific Cases of Sjogren's syndrome in France
  • 4.7. Italy
    • 4.7.1. Assumptions and Rationale
    • 4.7.2. Diagnosed Prevalent Cases of Sjogren's syndrome in Italy
    • 4.7.3. Gender-Specific Cases of Sjogren's syndrome in Italy
    • 4.7.4. Type-Specific Cases of Sjogren's syndrome in Italy
    • 4.7.5. Severity-Specific Cases of Sjogren's syndrome in Italy
  • 4.8. Spain
    • 4.8.1. Assumptions and Rationale
    • 4.8.2. Diagnosed Prevalent Cases of Sjogren's syndrome in Spain
    • 4.8.3. Gender-Specific Cases of Sjogren's syndrome in Spain
    • 4.8.4. Type-Specific Cases of Sjogren's syndrome in Spain
    • 4.8.5. Severity-Specific Cases of Sjogren's syndrome in Spain
  • 4.9. United Kingdom
    • 4.9.1. Assumptions and Rationale
    • 4.9.2. Diagnosed Prevalent Cases of Sjogren's syndrome in the United Kingdom
    • 4.9.3. Gender-Specific Cases of Sjogren's syndrome in the United Kingdom
    • 4.9.4. Type-Specific Cases of Sjogren's syndrome in the UK
    • 4.9.5. Severity-Specific Cases of Sjogren's syndrome in the United Kingdom
  • 4.10. Japan
    • 4.10.1. Assumptions and Rationale
    • 4.10.2. Diagnosed Prevalent Cases of Sjogren's syndrome in Japan
    • 4.10.3. Gender-Specific Cases of Sjogren's syndrome in Japan
    • 4.10.4. Type-Specific Cases of Sjogren's syndrome in Japan
    • 4.10.5. Severity-Specific Cases of Sjogren's syndrome in Japan

5. Current Treatment Practices

  • 5.1. United States Treatment Guidelines for Sjogren's Disease
  • 5.2. Evidence-based medicine clinical practice guidelines (US, EU, JP)

6. Unmet Needs

7. Marketed Drugs

  • 7.1. Salagen: ADVANZ Pharma
    • 7.1.1. Drug Description
    • 7.1.2. Regulatory Milestones
    • 7.1.3. Safety and Efficacy
    • 7.1.4. Product Profile
  • 7.2. Evoxac: Daiichi Sankyo
    • 7.2.1. Drug Description
    • 7.2.2. Regulatory Milestones
    • 7.2.3. Clinical Development
    • 7.2.4. Safety and Efficacy
    • 7.2.5. Product Profile

8. Emerging Therapies

  • 8.1. Key cross competition- Emerging Therapies
  • 8.2. RSLV-132: Resolve Therapeutics
    • 8.2.1. Drug Description
    • 8.2.2. Other Developmental Activities
    • 8.2.3. Clinical Development
    • 8.2.4. Safety and Efficacy
    • 8.2.5. Product Profile
  • 8.3. VAY736: Novartis/MorphoSys
    • 8.3.1. Drug Description
    • 8.3.2. Other Developmental Activities
    • 8.3.3. Clinical Development
    • 8.3.4. Safety and Efficacy
    • 8.3.5. Product Profile
  • 8.4. CFZ533: Novartis
    • 8.4.1. Drug Description
    • 8.4.2. Clinical Development
    • 8.4.3. Product Profile
  • 8.5. Belimumab: GlaxoSmithKline
    • 8.5.1. Drug Description
    • 8.5.2. Other Developmental Activities
    • 8.5.3. Clinical Development
    • 8.5.4. Safety and Efficacy
    • 8.5.5. Product Profile
  • 8.6. RO5459072: Roche
    • 8.6.1. Product Description
    • 8.6.2. Clinical Development
    • 8.6.3. Safety and Efficacy
    • 8.6.4. Product Profile
  • 8.7. LOU-064: Novartis
    • 8.7.1. Drug Description
    • 8.7.2. Clinical Development
    • 8.7.3. Product Profile
  • 8.8. Abatacept: Bristol Myers Squibb
    • 8.8.1. Product Description
    • 8.8.2. Other Development Activities
    • 8.8.3. Clinical Development
    • 8.8.4. Safety and Efficacy
    • 8.8.5. Product Profile
  • 8.9. Lacripep: TearSolutions
    • 8.9.1. Product Description
    • 8.9.2. Other Development Activities
    • 8.9.3. Clinical Development
    • 8.9.4. Product Profile
  • 8.10. Parsaclisib: Incyte Corporation
    • 8.10.1. Drug Description
    • 8.10.2. Other Development Activities
    • 8.10.3. Clinical Development
    • 8.10.4. Product Profile
  • 8.11. Filgotinib: Galapagos NV /Gilead Sciences
    • 8.11.1. Drug Description
    • 8.11.2. Other Developmental Activities
    • 8.11.3. Clinical Development
    • 8.11.4. Product Profile
  • 8.12. GS-9876: Gilead Sciences
    • 8.12.1. Drug Description
    • 8.12.2. Other Developmental Activities
    • 8.12.3. Clinical Development
    • 8.12.4. Product Profile
  • 8.13. VIB7734: VIELABIO
    • 8.13.1. Drug Description
    • 8.13.2. Other Developmental Activities
    • 8.13.3. Clinical Development
    • 8.13.4. Product Profile

9. Sjogren's Syndrome: 7 Major Market Analysis

  • 9.1. Key Findings
  • 9.2. Market Size of Sjogren's Syndrome in 7MM

10. Market Outlook by Country

11. The United States: Market Outlook

  • 11.1. United States Market Size
    • 11.1.1. Total Market Size of Sjogren's syndrome
    • 11.1.2. Market Size of Primary Sjogren's syndrome by Therapies
    • 11.1.3. Market Size of Secondary Sjogren's syndrome by Therapies

12. EU-5 Countries: Market Outlook

  • 12.1. Germany
    • 12.1.1. Total Market Size of Sjogren's syndrome
    • 12.1.2. Market Size of Primary Sjogren's syndrome by Therapies
    • 12.1.3. Market Size of Secondary Sjogren's syndrome by Therapies
  • 12.2. France
    • 12.2.1. Total Market Size of Sjogren's syndrome
    • 12.2.2. Market Size of Primary Sjogren's syndrome by Therapies
    • 12.2.3. Market Size of Secondary Sjogren's syndrome by Therapies
  • 12.3. Italy
    • 12.3.1. Total Market Size of Sjogren's syndrome
    • 12.3.2. Market Size of Primary Sjogren's syndrome by Therapies
    • 12.3.3. Market Size of Secondary Sjogren's syndrome by Therapies
  • 12.4. Spain
    • 12.4.1. Total Market Size of Sjogren's syndrome
    • 12.4.2. Market Size of Primary Sjogren's syndrome by Therapies
    • 12.4.3. Market Size of Secondary Sjogren's syndrome by Therapies
  • 12.5. United Kingdom
    • 12.5.1. Total Market Size of Sjogren's syndrome
    • 12.5.2. Market Size of Primary Sjogren's syndrome by Therapies
    • 12.5.3. Market Size of Secondary Sjogren's syndrome by Therapies
  • 12.6. Japan: Market Outlook
    • 12.6.1. Total Market Size of Sjogren's syndrome
    • 12.6.2. Market Size of Primary Sjogren's syndrome by Therapies
    • 12.6.3. Market Size of Secondary Sjogren's syndrome by Therapies

13. Market Drivers

14. Market Barriers

15. Appendix

16. Report Methodology

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

20. Disclaimer

Back to Top